The Immunomodulatory Role of Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Asthma
International Journal of Nanomedicine · 2026
DOI: 10.2147/ijn.s625070 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Nanomedicine, 2026. Verfasst von Furong You und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, People's Republic of China. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, Asthma, Exosomes. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Asthma is a chronic respiratory disease characterized by airway inflammation, hyperresponsiveness, and remodeling. Its pathogenesis is mainly related to immune imbalance, including Th1/Th2 and Th17/Treg imbalance, ILC2 activation and macrophage polarization, all of these contribute to airway inflammation and epithelial damage. Existing glucocorticosteroids and biologics have limited efficacy in non-Th2 or steroid-resistant patients, therefore new immunomodulatory strategies are urgently needed. Mesenchymal stem cell-derived exosomes (MSC-Exos), especially human umbilical cord MSC-Exos (HUCMSC-Exos), can regulate immune cell function, inhibit inflammasome activation, promote epithelial repair and attenuate airway remodeling and oxidative stress through a variety of active molecules such as proteins, miRNAs, lncRNAs and lipids. In animal and in vitro studies, MSC-Exos have shown good anti-inflammatory, immunomodulatory and tissue-protective effects, as well as low immunogenicity and good biocompatibility, providing a basis for clinical application. MSC-Exos are expected to become an innovative therapeutic strategy for asthma, especially for severe and steroid-resistant patients. However, the vast majority of current evidence remains limited to animal experiments and in vitro studies, and large-scale randomized controlled clinical trials are still lacking to verify its safety, efficacy, and standardized administration regimens in humans. Future researches should focus on defining the active ingredients, optimizing preparation and delivery methods, and conducting clinical validation to achieve multi-targeted and individualized immune interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, People's Republic of China.
- Key Laboratory of Birth Defects and Related Diseases of Women and Children of the Ministry of Education, Sichuan University, Chengdu, Sichuan, People's Republic of China.
ORCID-Profile: Furong You, Jingyu Guo
Zitieren
APA
You, F., Gao, Q., Li, W., Ma, N., Guo, J., & Li, X. (2026). The Immunomodulatory Role of Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Asthma. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s625070
Vancouver
You F, Gao Q, Li W, Ma N, Guo J, Li X. The Immunomodulatory Role of Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Asthma. International Journal of Nanomedicine. 2026. doi:10.2147/ijn.s625070
BibTeX
@article{You2026,
author = {You, Furong and Gao, Qian and Li, Wenxing and Ma, Na and Guo, Jingyu and Li, Xin},
title = {The Immunomodulatory Role of Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Asthma},
journal = {International Journal of Nanomedicine},
year = {2026},
doi = {10.2147/ijn.s625070}
}
EUVIMED